Skip to main content
Explore URMC

menu

Study of BHV-4157 in Alzheimer's Disease

Research Question:
Does the drug Riluzole (BHV-4157) help patients with Alzheimer's Disease?

Basic Study Information

Purpose:
Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect patients from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.

Location: University of Rochester Medical Center

Study Contact Information

Study Coordinator: Nancy Kowalski
Phone: (585) 760-6569
Email: Nancy_Kowalski@urmc.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search